Home Purchase Financing Forecast Raised

This and next year’s expected origination of loans to finance home purchases was modestly elevated. But projected 2017 refinances, however, retreated.

During the first-three months of this year, U.S. residential lenders are predicted to originate $350 billion in mortgages, including purchases and refinances.

National mortgage production is then expected to jump to $431 billion in the second quarter and $418 billion during the following three-month period.


…read more

From:: Financing

Democrats Hammer Mnuchin on One West Bank

President Donald Trump’s nominee for secretary of the Department of the Treasury took a beating yesterday from Senate Democrats over OneWest Bank.

Steven Mnuchin, Trump’s pick for Treasury secretary, spent more than five hours on Thursday at a Senate Finance Committee confirmation hearing.

Democrats on the committee grilled Mnuchin on the foreclosure practices at OneWest, which was created to take over failed IndyMac Bank FSB.


…read more

From:: Financing

MLK Holiday Drags Down Mortgage Business

With refinances leading the way, new mortgage activity moved lower in the week that included the Martin Luther King holiday.

In the week that ended on Jan. 20, the U.S Mortgage Market Index from OpenClose and Mortgage Daily landed at 122.

The index, an indication of upcoming residential loan originations, retreated nearly 7 percent compared to the previous week.


…read more

From:: Financing

Merck will pay $625 million and royalties to settle Keytruda patent litigation with Bristol-Myers Squibb and Ono Pharma

Merck & Co. Inc. will pay $625 million and royalties to Bristol-Myers Squibb Co. and Ono Pharmaceutical Co. Ltd. to settle patent litigation over Merck’s cancer drug Keytruda, the companies said Friday afternoon. As part of the settlement all patent litigation will be dismissed, and the companies have granted certain patent rights to each other. Merck will pay royalties on global Keytruda sales of 6.5% between 2017 and the end of 2023 and 2.5% between 2024 and 2026, with the royalties being split 75/25 between Bristol-Myers and Ono. Merck said the $625 million payment would be recorded in its fourth-quarter and full-year 2016 results, but excluded from its non-GAAP results. In their lawsuit against Merck, Bristol-Myers and Ono, which made cancer drug Opdivo, said its Keytruda sales infringed on various of its global patents. Bristol-Myers shares slumped 2.2% over the last three months, compared with a 1.0% rise in Merck shares and a 6.1% rise in the S&P 500 .

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

…read more

From:: Stock Market News

U.S. stocks close higher as Trump takes office

U.S. stocks closed higher Friday after coming off intraday highs as Donald Trump was sworn in as the 45th president of the U.S. In his inauguration speech, the new president reiterated his protectionist stance but did not offer details on how he would go about pursuing his agenda. The S&P 500 rose 7 points, or 0.3%, to close at 2,271 for a weekly decline of 0.2%. The Dow Jones Industrial Average gained 92 points, or 0.5%, to finish at 19,824, falling 0.3% for the week. The Nasdaq Composite Index advanced 15 points, or 0.3%, to close at 5,555, down shed 0.3% on the week.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

…read more

From:: Stock Market News